Under the terms of the partnership, UCB and Ariceum will utilize each other’s proprietary technology platforms to enable the discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer.
Ariceum will also gain access to UCB’s expertise to discover novel synthetic macrocyclic peptides using its mRNA-display technology platform, ExtremeDiversity.
In addition, UCB will benefit from Ariceum’s knowledge in the field of radiochemistry and labelling technology, to discover how this technology might lead to the discovery of products for immune-related diseases.
According to both companies, the research collaboration will give them the opportunity to explore several targets.
“We are excited about this strategic collaboration between UCB and Ariceum which aims to broaden Ariceum’s pipeline with potentially several new programs at discovery stage,” said Manfred Rüdiger, CEO of Arcieum.
“Through this partnership, Ariceum will have access to a unique library that will be used to screen against targets of interest for oncology for which current targeted approaches have failed, while working with UCB on enabling targeted systemic radiotherapy approaches in other areas of severe diseases.”
Dhaval Patel, chief scientific officer of UCB, added that the collaboration with Ariceum will further enhance UCB’s strategic drug discovery capabilities and provide it with the opportunity to learn and explore the potential of this modality, as it strives to “continuously innovate”.
